Alexion

News

Final hurdle falls as UK backs AZ's $39bn takeover of Alexio...

The UK's competition regulator has approved AstraZeneca's $39 billion acquisition of US-based drugmaker Alexion, without opting for a broader inquiry into the deal.

News

Another hurdle down as EU clears AstraZeneca's Alexion takeo...

The European Commission has given competition clearance to the $39 billion acquisition of Alexion by AstraZeneca, leaving the UK as the last remaining obstacle to getting the deal across th

News

EHA21: Novartis trumpets iptacopan as oral alternative to an...

The mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion's infusion therapy Soliris, but Novartis' iptacopan could provide an oral option afte

News

UK competition watchdog probes AstraZeneca, Alexion merger

The antitrust authority in the UK has launched an investigation into the proposed $39 billion takeover of US firm Alexion by AstraZeneca.

News

Apellis set to take on Alexion as FDA clears PNH drug Empave...

Apellis Pharma has secured FDA approval for its complement C3 inhibitor Empaveli as a treatment for paroxysmal nocturnal hemoglobinuria (PNH) – with a label that will allow it to challenge

News

Scotland backs NHS use of Alexion's Ultomiris for rare disea...

NHS patients in Scotland with the rare disease atypical haemolytic uremic syndrome (aHUS) will now be able to access treatment with Alexion's Ultomiris, ahead of their counterparts in Engla

Final hurdle falls as UK backs AZ's $39bn takeover of Alexio...

Another hurdle down as EU clears AstraZeneca's Alexion takeo...

EHA21: Novartis trumpets iptacopan as oral alternative to an...

UK competition watchdog probes AstraZeneca, Alexion merger

Apellis set to take on Alexion as FDA clears PNH drug Empave...

Scotland backs NHS use of Alexion's Ultomiris for rare disea...

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Alexion

Editor's Picks